Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

This is a study of DSP-0390 in patients with recurrent high grade glioma.

Inclusion Criteria: Estimated life expectancy \>+3 months Recovery from toxic effects of prior therapy to NCI CTCAE v5.0 Grade 1 (non-hematologic toxicities) or Grade \=70% Adequate organ function as determined by: * Absolute Neutrophil ≥1500/microliter (may not use G-CSF or GM CSF) * Platelet ≥100 × 103/microliter * Hemoglobin ≥9 g/dL (may not transfuse or use erythropoietin to obtain this Hgb level) * Creatinine Clearance ≥ 40ml/min (Cockcroft-Gault) * Total bilirubin ≤1.5 times ULN (or ≤ 2 times ULN for patients with known Gilbert's syndrome) * AST ≤ 3 times ULN * ALT ≤ 3 times ULN * INR, PT, PTT, or aPTT ≤1.5 x ULN Note: The use of anticoagulants is permitted as long as the PT/(a)PTT is within therapeutic limits (according to the local institution standard) and the patient has been on a stable anticoagulant regimen for at least 2 weeks prior to study Day 1. If on antiepileptic drug; dose must be stable and no seizures 14 days prior to study Day 1 If on corticosteroids at baseline, dose must be stable or decreasing for at least 5 days prior to study Day 1. For the dose expansion part of the study, the dose must be ≤ 4 mg dexamethasone per day (or equivalent dose if other corticosteroids are used). A higher stable dose of corticosteroids, if used as HRT, may be allowed upon discussion with the Medical Monitor. Females of childbearing potential must have a negative serum or urine pregnancy test Male or female patients of child-producing potential must agree to use contraception or use prevention of pregnancy measures or agreement to refrain completely from heterosexual intercourse during the study and for 6 months (females \& males) after the last dose of study drug Exclusion Criteria: Prior therapy with bevacizumab or other anti-vascular endothelial growth factor (VEGF) treatments within 3 months prior to study Day 1, Multifocal disease, leptomeningeal metastasis, or extracranial metastasis Abnormal ECGs that are clinically significant, including those where QT prolongation (QTcF\>450 msec for males and \>470 msec for females); and/or history of Torsade de Pointes Left ventricular ejection fraction \